The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival compared with neoadjuvant chemo and interval cytoreductive surgery.

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

“This marks the first time a [pembrolizumab]-based regimen has shown the ability to help certain patients with platinum-resistant ovarian cancer live longer, and the first time an immune checkpoint ...

TAMPA, Fla. — A new study of a cancer treatment called HIPEC, heated intraperitoneal chemotherapy, is showing good results when it comes to treating women with metastatic epithelial ovarian ...

Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial will determine ...

HOPE for patients and providers. Ovarian cancer is the eighth-most common cancer for women in the U.S., but the fifth leading cause of cancer death for women, according to the National Cancer ...

In addition to the ovarian cancer study, ArtemiCafe Decaf is also being tested in a separate phase 2 trial for prostate cancer maintenance therapy at the same center.

During her presentation, Moore highlighted the first ADC to enter the ovarian cancer space following the 2024 full FDA approval of mirvetuximab soravtansine-gynx (Elahere) for the treatment of adult ...